| Hormone refractory prostate cancer
Lynparza vs Provenge
Side-by-side clinical, coverage, and cost comparison for hormone refractory prostate cancer.Deep comparison between: Lynparza vs Provenge with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsProvenge has a higher rate of injection site reactions vs Lynparza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Provenge but not Lynparza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lynparza
Provenge
At A Glance
Oral
Twice daily
PARP inhibitor
IV infusion
Every 2 weeks
Autologous cellular immunotherapy
Indications
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
- Malignant neoplasm of breast
- Adenocarcinoma of pancreas
- Hormone refractory prostate cancer
- Hormone refractory prostate cancer
Dosing
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line BRCAm maintenance) 300 mg orally twice daily; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line HRD-positive, + bevacizumab) 300 mg orally twice daily with bevacizumab 15 mg/kg every 3 weeks; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent BRCAm maintenance) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Malignant neoplasm of breast (adjuvant, gBRCAm HER2-negative high risk early) 300 mg orally twice daily for a total of 1 year, or until disease recurrence or unacceptable toxicity.
Malignant neoplasm of breast (metastatic, gBRCAm HER2-negative) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Adenocarcinoma of pancreas 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (HRR gene-mutated mCRPC, monotherapy) 300 mg orally twice daily with concurrent GnRH analog or prior bilateral orchiectomy; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (BRCAm mCRPC, + abiraterone) 300 mg orally twice daily with abiraterone 1000 mg once daily and prednisone or prednisolone 5 mg twice daily; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 3 complete doses at approximately 2-week intervals; each dose infused IV over approximately 60 minutes; premedicate with acetaminophen and antihistamine approximately 30 minutes prior to infusion.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, thrombocytopenia
Serious myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, venous thromboembolism, hepatotoxicity including drug-induced liver injury
Postmarketing drug-induced liver injury, hypersensitivity including angioedema, erythema nodosum, rash, dermatitis
Most common (>=15%) Chills, fatigue, fever, back pain, nausea, joint ache, headache
Serious Acute infusion reactions, cerebrovascular events, eosinophilia, rhabdomyolysis, myasthenia gravis, myositis, tumor flare
Postmarketing Syncope, transient ischemic attack, strokes, hypotension, myocardial infarction, deep venous thrombosis, pulmonary embolism
Pharmacology
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes (PARP1, PARP2, PARP3) involved in DNA transcription and repair; cytotoxicity occurs through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, with enhanced activity in tumor cells harboring deficiencies in BRCA1/2, ATM, or other homologous recombination repair (HRR) genes.
PROVENGE is an autologous cellular immunotherapy designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers; APCs are activated ex vivo with the PAP-GM-CSF fusion protein, take up and process the recombinant antigen, and display it on the cell surface to stimulate T cell and antibody responses.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lynparza
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Provenge
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lynparza
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Provenge
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lynparza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Provenge
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Lynparza Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LynparzaView full Lynparza profile
ProvengeView full Provenge profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.